Original Article

You have full text access to this OnlineOpen article

Estimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US national osteoporosis foundation guidelines

  1. Meghan G Donaldson1,*,
  2. Peggy M Cawthon1,
  3. Lily Y Lui1,
  4. John T Schousboe2,
  5. Kristine E Ensrud3,
  6. Brent C Taylor3,
  7. Jane A Cauley4,
  8. Teresa A Hillier5,
  9. Thuy T Dam6,
  10. Jeff R Curtis7,
  11. Dennis M Black8,
  12. Douglas C Bauer8,
  13. Eric S Orwoll9,
  14. Steven R Cummings1,8

Article first published online: 4 FEB 2010

DOI: 10.1002/jbmr.55

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 25, Issue 7, pages 1506–1511, July 2010

Additional Information

How to Cite

Donaldson, M. G., Cawthon, P. M., Lui, L. Y., Schousboe, J. T., Ensrud, K. E., Taylor, B. C., Cauley, J. A., Hillier, T. A., Dam, T. T., Curtis, J. R., Black, D. M., Bauer, D. C., Orwoll, E. S. and Cummings, S. R. (2010), Estimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US national osteoporosis foundation guidelines. Journal of Bone and Mineral Research, 25: 1506–1511. doi: 10.1002/jbmr.55

Author Information

  1. 1

    San Francisco Coordinating Center, California Pacific Medical Center, San Francisco, CA, USA

  2. 2

    Park Nicollet Health Services and Division of Health Policy and Management, University of Minnesota, Minneapolis, MN, USA

  3. 3

    University of Minnesota and CCDOR VA Medical Center, Department of Medicine, Minneapolis, MN, USA

  4. 4

    University of Pittsburgh, Pittsburgh PA, USA

  5. 5

    Kaiser Permanente Center for Health Research , Portland, OR, USA

  6. 6

    Division of Geriatrics and Aging, Columbia University, New York, NY, USA

  7. 7

    University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL, USA

  8. 8

    University of California San Francisco, Department of Epidemiology and Biostatistics, San Francisco, CA, USA

  9. 9

    Oregon Health and Science University, Department of Medicine, Portland, OR, USA

*San Francisco Coordinating Center, California Pacific Medical Center, 185 Berry Street, Suite 5700, Lobby 5, San Francisco, CA 94107, USA.

Publication History

  1. Issue published online: 30 JUN 2010
  2. Article first published online: 4 FEB 2010
  3. Manuscript Accepted: 26 JAN 2010
  4. Manuscript Revised: 5 OCT 2009
  5. Manuscript Received: 7 JUL 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (74K)

References

  • 1
    National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation, 2008.
  • 2
    World Health Organisation. FRAX: WHO Fracture Risk Assessment Tool. Geneva: WHO, 2008.
  • 3
    Cummings SR, Cawthon PM, Ensrud KE, Cauley JA, Fink HA, Orwoll ES. BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison with older women. J Bone Miner Res. 2006; 21: 1550–1556.
    Direct Link:
  • 4
    Fink HA, Blackwell TL, Taylor BC, et al. Distribution and rate of clinical fracture in older men without osteoporosis: the Osteoporotic Fractures in Men Study (MrOS). J Bone Miner Res. 2008; 23: S79.
  • 5
    Donaldson M, Cawthon P, Lui L, et al. Estimates of the proportion of older white women who would be recommended for pharmacologic treatment by the new US National Osteoporosis Foundation guidelines. J Bone Miner Res. 2010.
    Direct Link:
  • 6
    Orwoll E, Blank JB, Barrett-Connor E, et al. Design and baseline characteristics of the Osteoporotic Fractures in Men Study (MrOS): a large observational study of the determinants of fracture in older men. Contemp Clin Trials. 2005; 26: 569–585.
  • 7
    Blank JB, Cawthon PM, Carrion-Petersen ML, et al. Overview of recruitment for the Osteoporotic Fractures in Men Study (MrOS). Contemp Clin Trials. 2005; 26: 557–568.
  • 8
    Looker AC, Wahner HW, Dunn WL, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int. 1998; 8: 468–489.
  • 9
    Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008; 19: 385–397.
  • 10
    Richards JB, Leslie WD, Joseph L, et al. Changes to osteoporosis prevalence according to method of risk assessment. J Bone Miner Res. 2007; 22: 228–234.
    Direct Link:
  • 11
    Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, et al. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int. 2008; 19: 437–447.
  • 12
    MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008; 148: 197–213.
  • 13
    Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000; 343: 604–610.
  • 14
    Ringe JD, Dorst A, Faber H, Ibach K. Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int. 2004; 24: 110–113.
  • 15
    Ringe JD, Faber H, Farahmand P, Dorst A. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int. 2006; 26: 427–431.
  • 16
    Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res. 2009; 24: 719–725.
    Direct Link:
  • 17
    Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003; 18: 9–17.
    Direct Link:
  • 18
    Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab. 2000; 85: 3069–3076.
View Full Article (HTML) Get PDF (74K)